Data is required for the successful treatment of cancer. According to Eric Lefkofsky there is not enough data available. For this reason he established Tempus. The company’s goal is the establishment of databases of information to aid in cancer treatment. Mr Lefkofsky believes the data must combine therapeutic data and genomic information.
Lefkofsky became interested in cancer research when his wife was diagnosed with cancer. He realized doctors often do not have the data they require to give their patients the best possible treatment. This is where Tempus will help. The company is using existing medical records and pathology systems to establish a data pool. This establishes the existing patterns between the current treatments and their results.
Lefkofsky gives a perfect example as to why this data is so critical. In the case of a group of patients with breast cancer taking Herceptin there is no way to know why the drug worked on forty percent of the patients but not the other sixty. Additional data explaining what is happening with the patients who are not responding is needed. They may be on other drugs or diabetic. Without the additional data this is not clear.
Eric Lefkofsky is the CEO and one of the founders of Tempus. He is also one of the founding partners of Lightbank. This is a venture fund who invests in the field of disruptive technologies. Lefkofsky is also recognized as one of the founders of Groupon and Uptake technologies.
Lefkofsky and his wife Liz established the LefkofskyFamily Foundation in 2016. This is a charitable foundation that enhances the lives of the people in the communities they are involved in. He holds the position of Trustee for the Lurie Children’s Hospital located in Chicago, Illinois and is the Chairman of the Board for the Steppenwolf Theatre Company also located in Chicago. Lefkofsky works at the University of Chicago as an adjunct professor and has written the Accelerated Disruption. Lefkofsky is a graduate of the University of Michigan and also attended the University of Michigan Law School where he earned his Juris Doctor.
– Co-founder and CEO @ Tempus | Crunchbase
Oncotarget is a medical journal, which was founded in 2010. The journal is published on a weekly basis. It covers all issues related to oncology. Oncotarget’s chief editors are Andrei Gudkov and Mikhail Blagosklonny of Institute of Cancer, Roswell Park. The journal applies a standardized license to its publications. Authors are allowed to maintain ownership rights of their articles. They can give permission to anyone to download, modify, copy, reuse, reprint and distribute their submitted materials. The editors and the publisher expect the authors to adhere to the stipulated ethical considerations to qualify to submit their articles to Oncotarget. By following the set standards, the journal ensures that only legit articles having accurate information are published.
To begin with, authors must describe the accurate results of their research and give the scientific explanation of their work. The submitted document should have enough references and details that allow others to reproduce them. The opinion of the editors should be acknowledged and the reviewed articles portray objectivity, accuracy and comprehensiveness. Authors who intentionally submit false or inaccurate information will be considered unethical. Oncotarget is published by Impact Journals
On the same note, persons listed as authors must be responsible to the public in their conception, proposal, acquisition, implementation, analysis and interpretation of data. Similarly, they must have gone through and approved the final copy of the manuscript, and accept that it should be submitted for publication. Notably, the persons that contributed ideas on the paper and do not meet the requirements for authorship should not be listed as authors. The authors should instead recognize them in the acknowledgment section.
Consequentially, writers should give proper recognition to other contributors in their work. They should also provide citations of the sources that they used to complete their papers. Privately owned information from correspondence, discussion, and conversation with third parties must only be used after obtaining their permission. Nevertheless, writers should avoid using information from confidential sources like grand applications and refereeing manuscripts unless they have received written authorization of the authors who were involved in that work. Conclusively, authors that publish their papers through Oncotarget have an obligation to inform the editors or publisher when they discover inaccuracies or significant errors after they have already submitted their work. Download output styles at Endnote.com
Dr. Clay Siegall currently serves in three positions in Seattle Genetics a company he co-founded, he is the CEO, the Chairman as well as the president. He did not just get to this positions he had interest in the field, he attained a B.S degree in Zoology from Maryland University and went ahead to get a P.H.D in Genetics this is after achieving his doctorate from the University of Washington. Further, he has experience in the medical fields as he has worked for nearly a decade for two medical research centers. Also, he serves as a board member to several private biotechnology companies such as Alder Biopharmaceuticals, Ultragenyx Pharmaceuticals, and Mirna Therapeutics.
On Dec 7, 2016 Smartmoney posted an article about Dr. Clay and Seattle Genetics looking at the company net worth and the company contribution to the cancer world. According to the article, Clay is a man to be celebrated for contributing to cancer research intensively currently holding 15 patents and has 70 publications on cancer research. Further, according to the article, DR.Clay does hold a prestigious position in the greatest Cancer Research & Development Centers that is Seattle Genetics. The company is into biotechnology but specializes in commercialization and development of antibody based therapy. The company has included a very beneficial drug, an antibody in their therapy that conjugates and directly injects cancer cells with killing agents. The company is not only succeeding in cancer treatment but it is contributing to the economy, and as of 2016, the company estimated net worth was $ 4.7 Billion. The company is indeed ready for commercialization.